tirzepatide compounded with b6 Vial | Weight Loss Treatment 1 and GIP therapy Axis Health

Weight outcomes included the absolute and percent changes in weight from the index date to 1 year of post-index follow-up (index date + 365 days)

Individualized Approach To ensure the best treatment results, it is crucial to provide personalized care for each patient undergoing Tirzepatide therapy

The HRs comparing tirzepatide to the control were 0.80 (95% CI, 0.57-1.11) for MACE-4, 0.90 (95% CI, 0.50-1.61) for cardiovascular death, and 0.80 (95% CI, 0.51-1.25) for all-cause death

If you find your vial has accidentally frozen, it must be discarded

Days 6 to 7 post-injection represent the waning period

Response-based titration means some people never go above 4 or 5 mg daily sublingual